Delivery of the project on the Research of the neuroprotective effects of the new therapeutic agents on retinal photoreceptor cells
The project on the Research of the neuroprotective effects of the new therapeutic agents on retinal photoreceptor cells carried out by Norameda.
UAB Norameda has implemented a project on the Research of the neuroprotective effects of the new therapeutic agents on retinal photoreceptor cells (hereinafter – the Project) which developed a method that can be used to detect neuroprotective effects by analyzing various recombinant and natural proteins with varying degrees of neuroprotective activity.
The project was delivered in 5 months.
The successful implementation of the project opens up the possibility to develop a completely new technology for testing and evaluating newly developed products for the treatment of visual impairments, while creating conditions for the development of an innovative product. Also, this project gives UAB Norameda a competitive edge not only in Lithuania, but also in the Baltic States.
The Project was funded under Inočekiai LT instrument VP2-1.3-ŪM-05-K of the Agency for Science, Innovation and Technology aimed at start-ups or SMEs engaged in innovative activities whereupon they are entitled to receive a targeted financial support of a fixed amount for purchase of services from science and research institutions. Objective of the instrument: to increase the competitiveness of the country’s economy, business productivity and the comparative share of high value-added business, to encourage small and medium-sized enterprises (SMEs) to carry out innovative activities, to promote scientific and business cooperation.